Can You Test for Perimenopause? Diagnosis & Hormone Testing

Why Perimenopause Is Difficult to Diagnose With One Test

Perimenopause does not produce a single clean biomarker the way type 1 diabetes produces anti-GAD antibodies or hypothyroidism produces an elevated TSH. The ovaries wind down erratically. Estradiol can surge to supraphysiologic levels one cycle, then crash the next. Because of that volatility, a snapshot blood draw often misleads rather than clarifies.

The Menopause Society (formerly NAMS) states in its 2023 position statement that "the diagnosis of menopause and the menopausal transition is primarily clinical" and that laboratory testing "should be used to rule out other conditions rather than to confirm the transition" in women who are the expected age and have characteristic symptoms [1].

That framing matters for patients. If your FSH comes back at 18 IU/L and you have hot flashes and irregular cycles at age 46, you are almost certainly perimenopausal even though 18 IU/L sits below many labs' postmenopausal reference range. The clinical picture outweighs any single number.

Why Hormone Levels Fluctuate So Much

During the early menopausal transition, the pituitary releases higher pulses of follicle-stimulating hormone to recruit follicles that are becoming harder to stimulate. But some cycles still produce a dominant follicle that secretes substantial estradiol, temporarily suppressing FSH back into the normal premenopausal range. This cycle-to-cycle variation means an FSH drawn on day 3 of one cycle might be 40 IU/L and drawn three months later might be 12 IU/L.

The SWAN (Study of Women's Health Across the Nation) cohort followed 3,302 women longitudinally and documented that FSH variability increases sharply in the two to three years before the final menstrual period [2]. Single-point measurements miss that variability entirely.

What STRAW+10 Tells Clinicians

The Stages of Reproductive Aging Workshop +10 (STRAW+10) criteria, published in Fertility and Sterility, define seven stages of female reproductive aging from peak reproductive years through postmenopause [3]. Clinicians use these criteria to assign a stage based on:

• Menstrual cycle length changes (a persistent 7-day or greater difference from usual cycle length signals early transition)
• Cycle skipping (60 or more days without a period indicates late transition)
• Hormone markers as supporting evidence, not primary criteria

STRAW+10 is the framework the Endocrine Society, the American College of Obstetricians and Gynecologists (ACOG), and the Menopause Society all reference when they describe staging the menopausal transition.

Which Blood Tests Are Actually Ordered

A standard perimenopause workup typically includes four to six markers drawn on cycle day 2 or 3 when a regular cycle still exists, or at any point when cycles are irregular.

FSH (Follicle-Stimulating Hormone)

FSH is the most commonly ordered perimenopause marker. As ovarian reserve declines, the pituitary secretes more FSH to compensate. A value above 25 IU/L on two separate measurements at least four weeks apart is consistent with the menopausal transition per the 2023 Menopause Society guidelines [1].

FSH has limitations. Oral contraceptive pills suppress FSH into the normal range even in women who are perimenopausal. Women on combined hormonal contraception cannot be staged by FSH while taking the pill.

Estradiol (E2)

Estradiol levels drop on average across the menopausal transition, but day-to-day variation is so wide that a single low value does not confirm perimenopause and a single high value does not exclude it. Estradiol below 20 pg/mL in the absence of exogenous estrogen is more consistent with postmenopause, but that threshold has poor sensitivity during the transition itself.

Estradiol is most useful when combined with FSH. Elevated FSH alongside low estradiol provides stronger evidence than either marker alone.

AMH (Anti-Müllerian Hormone)

Anti-Müllerian hormone is secreted by small antral follicles and declines progressively as ovarian reserve falls. Unlike FSH, AMH does not fluctuate substantially across the menstrual cycle, making it a more stable biomarker. A 2020 study published in the Journal of Clinical Endocrinology and Metabolism (N=1,537) found that AMH predicted the age at menopause within a two-year window with reasonable accuracy, outperforming FSH for this purpose [4].

AMH levels below 0.1 ng/mL are associated with imminent menopause. The test is not yet universally covered by insurance for perimenopause evaluation specifically, though it has broader coverage for fertility assessment.

Inhibin B

Inhibin B, produced by granulosa cells, falls earlier in the transition than FSH rises. It is less commonly ordered in clinical practice but appears in research protocols. Its primary value is in fertility workups where ovarian reserve assessment is the main goal.

TSH (Thyroid-Stimulating Hormone)

Hypothyroidism affects approximately 10 percent of women over 40 and produces fatigue, irregular periods, brain fog, weight gain, and sleep disruption. Those symptoms overlap almost entirely with perimenopause. The American Thyroid Association recommends TSH screening in symptomatic women, and ACOG's 2021 committee opinion on managing menopausal symptoms lists thyroid disease as a primary condition to exclude before attributing symptoms to the menopausal transition [5].

A normal TSH (0.45 to 4.5 mIU/L per most laboratory reference ranges) rules out overt thyroid dysfunction. Subclinical hypothyroidism, defined as TSH above 4.5 mIU/L with normal free T4, may still warrant treatment depending on symptoms and cardiovascular risk.

Additional Labs Worth Ordering

A complete workup may also include:

• Complete metabolic panel to assess fasting glucose and liver function, relevant if hormone therapy is being considered
• Lipid panel, because estrogen loss accelerates cardiovascular risk
• Complete blood count to rule out anemia as a fatigue cause
• Prolactin if galactorrhea or amenorrhea without other explanation is present
• Testosterone (total and free) if low libido is a primary complaint, since androgen decline parallels estrogen decline during the transition

How Symptoms Combine With Lab Values in Clinical Practice

Symptoms carry more diagnostic weight than many patients expect. The Menopause Society's 2023 guidelines describe vasomotor symptoms (hot flashes and night sweats) as having roughly 75 percent specificity for the late menopausal transition in women aged 45 to 55 [1]. That means three out of four women with classic hot flashes and cycle irregularity at that age are genuinely perimenopausal, even before a single lab result returns.

The Core Symptom Cluster

The symptoms most strongly associated with perimenopause in population studies include:

• Vasomotor symptoms: hot flashes occurring more than two times per week, night sweats disrupting sleep
• Menstrual irregularity: cycle length varying by 7 or more days in either direction
• Sleep disturbance independent of night sweats
• Mood changes, particularly increased anxiety or low mood in the premenstrual window
• Genitourinary symptoms: vaginal dryness, dyspareunia, increased urinary urgency

The Penn Ovarian Aging Study followed 436 women from premenopause through postmenopause over 14 years and found that hot flash prevalence peaked in the late transition and early postmenopause, reaching 82 percent in the year immediately before the final period [6]. Symptom timing is itself diagnostic information.

When Lab Values Contradict Symptoms

A woman aged 48 with classic vasomotor symptoms and cycles now arriving every 40 to 60 days does not need an FSH of 40 IU/L to receive a perimenopause diagnosis and a treatment discussion. But if her FSH comes back at 8 IU/L, that finding warrants a conversation about other explanations, not a dismissal of her experience.

ACOG's 2022 practice bulletin on menopause management notes that "laboratory testing is generally unnecessary in women aged 45 years and older with typical menopausal symptoms" but is "reasonable in women younger than 45 years or in cases where the diagnosis is uncertain" [7].

Testing in Women Under 45: A Different Calculus

Women who develop perimenopausal symptoms before age 45 require a more thorough workup because the differential is wider. Premature ovarian insufficiency (POI), previously called premature menopause, affects approximately 1 in 100 women before age 40 and 1 in 1,000 before age 30 [8].

Ruling Out Premature Ovarian Insufficiency

The European Society of Human Reproduction and Embryology (ESHRE) guideline on POI (2016, updated) defines POI as FSH above 25 IU/L on two measurements at least four weeks apart in a woman under 40 with oligo/amenorrhea for at least four months [9]. Women aged 40 to 45 with the same picture fall into a "early menopause" category that warrants the same thorough evaluation.

POI has specific causes that standard perimenopause does not. An evaluation for a woman under 45 with elevated FSH typically adds:

• Karyotype (to exclude Turner syndrome mosaicism)
• FMR1 premutation testing (fragile X carrier status)
• Adrenal antibodies (21-hydroxylase antibodies)
• Anti-ovarian antibodies in some protocols

Missing POI has real consequences. Women with POI have significantly higher risks for osteoporosis and cardiovascular disease compared with women who reach natural menopause at the expected age, and hormone therapy is recommended at least until age 51 in confirmed POI [9].

Fertility Implications

A woman under 45 with irregular cycles and a rising FSH asking whether she can still conceive deserves a specific answer: ovulation can still occur unpredictably during the early menopausal transition, but the probability declines substantially. AMH below 0.5 ng/mL is associated with a markedly reduced ovarian reserve. Fertility consultation is appropriate before that window closes if pregnancy is desired.

Over-the-Counter and At-Home Testing Options

Several over-the-counter FSH urine tests are sold in pharmacies and online, including the Clearblue Menopause Stage Indicator and generic FSH test strips. These detect FSH above a fixed threshold, typically around 25 IU/L, using a mid-stream urine sample.

What Home Tests Can and Cannot Do

A positive home FSH test means FSH is elevated in that urine sample on that day. It does not:

• Confirm perimenopause stage per STRAW+10 criteria
• Distinguish early transition from late transition from postmenopause
• Account for day-to-day FSH variability
• Replace estradiol, AMH, or TSH measurements

The FDA cleared the Clearblue Menopause Stage Indicator in 2023 as the first over-the-counter device designed to provide stage-specific information using a 10-day urinary FSH tracking protocol [10]. The algorithm uses the pattern of FSH across 10 consecutive mornings to assign one of four stages. This represents an improvement over a single-threshold strip, but the company's own labeling notes that results should be discussed with a clinician before making treatment decisions.

Home tests serve best as a prompt to seek care, not as a replacement for care.

What Happens After Diagnosis: Connecting Testing to Treatment

A perimenopause diagnosis opens a clinical decision tree. The most consequential branch is whether hormone therapy is appropriate.

The Hormone Therapy Conversation

The 2023 Menopause Society position statement concludes that "for women aged younger than 60 years or who are within 10 years of menopause onset, and who have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for prevention of bone loss" [1]. That statement reversed much of the post-Women's Health Initiative overcaution that had persisted since 2002.

Contraindications to systemic estrogen include unexplained vaginal bleeding, active liver disease, a personal history of estrogen-receptor-positive breast cancer, and active venous thromboembolism. These are assessed during the same clinical visit that reviews hormone results.

Non-Hormonal Options for Symptomatic Perimenopause

For women who cannot or choose not to use hormone therapy, FDA-approved non-hormonal options for vasomotor symptoms now include:

• Fezolinetant (Veozah), a neurokinin 3 receptor antagonist approved by the FDA in May 2023, dosed at 45 mg orally once daily. In the SKYLIGHT-1 trial (N=501), fezolinetant reduced moderate-to-severe hot flash frequency by 59 percent from baseline at week 12 versus 40 percent for placebo (P<0.001) [11].
• Paroxetine 7.5 mg (Brisdelle), the only SSRI with an FDA indication specifically for vasomotor symptoms
• Cognitive behavioral therapy, which reduced hot flash interference scores by 46 percent in the MENOS-4 trial [12]

Bone Density Screening Timing

The U.S. Preventive Services Task Force recommends bone density screening (DEXA scan) beginning at age 65 for average-risk women, but earlier screening at age 50 to 64 is appropriate for women with risk factors including early menopause [13]. A perimenopause diagnosis is the right time to calculate fracture risk using the FRAX tool, which is available at the WHO Collaborating Centre website and factors in age, BMI, prior fractures, and smoking status.

A Practical Testing Timeline for Clinicians and Patients

The sequence below reflects how a board-certified gynecologist or internist might approach this workup for a woman aged 45 to 52 with new symptoms.

Visit 1: History and symptom scoring (the validated Menopause Rating Scale or Greene Climacteric Scale), menstrual calendar review, TSH, CBC, metabolic panel, lipids, FSH, estradiol.

4 to 6 weeks later: Repeat FSH and estradiol if initial FSH was borderline (10 to 24 IU/L) and symptoms continue. Add AMH if pregnancy planning is relevant or if staging certainty would change management.

Ongoing: Annual TSH if baseline was normal but symptoms persist or evolve. DEXA if risk factors are present. Lipid panel every one to three years based on cardiovascular risk profile.

For women under 45: add karyotype, FMR1 testing, and adrenal antibodies at Visit 1 if FSH is elevated, per ESHRE POI guidelines.